There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Antibe Therapeutics (ATBPF – Research Report) and Kezar Life Sciences (KZR – Research Report) with bullish sentiments.
Antibe Therapeutics (ATBPF)
Echelon Wealth Partners analyst Stefan Quenneville maintained a Buy rating on Antibe Therapeutics today and set a price target of C$2.00. The company’s shares closed last Monday at $0.66.
Quenneville has an average return of
According to TipRanks.com, Quenneville is ranked #7514 out of 8631 analysts.
Antibe Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $1.45.
See Insiders’ Hot Stocks on TipRanks >>
Kezar Life Sciences (KZR)
TD Cowen analyst Phil Nadeau maintained a Buy rating on Kezar Life Sciences today. The company’s shares closed last Monday at $0.73, close to its 52-week low of $0.70.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of
Kezar Life Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $20.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
